Welcome to our dedicated page for Propanc Biopharma SEC filings (Ticker: PPCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Propanc Biopharma, Inc. filings document a development-stage biopharmaceutical issuer centered on PRP, a proenzyme formulation using trypsinogen and chymotrypsinogen for recurrent and metastatic cancer programs. Registration statements and amendments disclose the company’s business, financial statements, clinical-development plans, risk factors, offering terms, and capital needs.
Material-event reports cover financing and governance actions, including Series C Preferred Stock, related warrants, amendments to charter documents, board changes, and Nasdaq listing-compliance notices. The filing record also details capitalization, preferred-stock rights and conversion mechanics, unregistered equity sales, and public-company reporting obligations tied to Propanc’s oncology development strategy.
Propanc Biopharma, Inc. (PPCB) reports that its Board and the holder of a majority of its voting power approved, by written consent dated July 24, 2026, the issuance of restricted shares of common stock to officers, directors and service providers in order to recognize recent achievements and provide incentives.
The awards include 1,000,000 restricted shares to CEO and director James Nathanielsz and multiple grants of 250,000 restricted shares each to various executives, directors, consultants and professional service firms. The approvals are intended to comply with NASDAQ Listing Rules 5635(b) and 5635(c) because PPCB’s common stock trades on the NASDAQ Capital Market and the new issuances implicate NASDAQ’s stockholder-approval standards.
As of July 24, 2026, there were 3,503,116 common shares outstanding and 1 share of Series B Preferred Stock. The Majority Stockholder, James Nathanielsz, held 400,000 common shares and the sole Series B share, representing approximately 50.001% of PPCB’s voting equity, and approved the actions by written consent. No meeting or proxies are being solicited, the actions become effective 20 days after mailing the information statement, and stockholders do not have dissenter’s or appraisal rights for these issuances.
Propanc Biopharma, Inc. obtained stockholder approval by written consent on July 24, 2026 to issue new restricted shares of Common Stock and to implement a reverse stock split, in order to comply with NASDAQ Listing Rules 5635(b) and 5635(c) and maintain its NASDAQ Capital Market listing.
The Board approved restricted share grants to officers, directors and service providers, including 1,000,000 restricted shares to CEO James Nathanielsz and several grants of 250,000 restricted shares to other named recipients. As of July 24, 2026 there were 3,503,116 Common shares and 1 Series B Preferred share outstanding, with the Majority Stockholder holding 400,000 Common shares and the sole Series B Preferred share, representing about 50.001% of voting equity. The actions approved by written consent will become effective 20 calendar days after the first mailing of the Information Statement, and stockholders are not being asked for proxies or granted dissenter’s rights.
Propanc Biopharma, Inc. is registering up to 2,500,000 shares of Common Stock for resale by Hexstone Capital LLC. These shares are issuable upon conversion of up to 9,900 shares of Series C Preferred Stock that may be acquired through a warrant.
Propanc already received $1,000,000 in gross proceeds from issuing 100 Series C Preferred shares and the warrant, and would receive up to $99,000,000 more if the warrant is fully exercised for cash. The company will not receive proceeds from selling stockholder resales. The Series C converts at the lesser of $125.00 or 85% of a volume-based market price, floored at $12.50, subject to a 4.99% (or 9.99% on notice) beneficial ownership cap and a 9,500,000-share reserve.
Shares outstanding were 3,503,116 as of July 6, 2026, or 6,003,116 if all registered shares are issued. Propanc reports no revenue, a nine‑month net loss of $15,221,714, an accumulated deficit of $140,843,234, cash of $443,702, and substantial doubt about its ability to continue as a going concern.
Propanc Biopharma, Inc. reported that effective July 8, 2026, Annie Van Broekhoven retired and stepped down from its Board of Directors, and the company accepted her resignation. The Board simultaneously filled the resulting vacancy.
The Board appointed Carlo Campiciano to serve as a director until his resignation or removal. Campiciano is a qualified accountant and member of the Institute of Public Accountants in Australia, with a Master of Entrepreneurship and Innovation and US GAAP certification. He previously served as CFO and Company Secretary of ASX-listed MedAdvisor Limited, where he helped raise multiple rounds of capital and supported the company’s ASX listing and international expansion. The company and Campiciano entered into a Director Agreement dated July 8, 2026, included as an exhibit.
Propanc Biopharma reported no revenue for the quarter ended March 31, 2026 and remains a development‑stage oncology company focused on its preclinical PRP pro‑enzyme candidate. The company posted a quarterly net loss of $6.36 million and a nine‑month net loss of $14.29 million, driven largely by stock‑based administrative expenses.
Cash increased to $443,702 at March 31, 2026 from $12,088 at June 30, 2025, supported by financing inflows including a common stock offering and issuance of Series C Preferred Stock and related warrants. Total assets were $14.33 million, mostly prepaid equity‑settled service costs, while total liabilities were $3.51 million and stockholders’ equity was $9.83 million.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses, negative operating cash flow of $4.08 million over nine months, and a cumulative deficit of $140.84 million. As of May 14, 2026 there were 56,959,280 common shares outstanding, reflecting significant recent equity issuance and conversions.
Propanc Biopharma, Inc. has filed a resale registration statement covering up to 15,000,000 shares of common stock for a single selling stockholder, Hexstone Capital LLC. These shares are issuable upon conversion of Series C Preferred Stock already issued or issuable under a warrant.
The company will not receive proceeds from any resale of these shares, only from potential future cash exercises of the warrant. Propanc is a development‑stage oncology company focused on its lead candidate PRP for pancreatic, ovarian and colorectal cancers, with no revenue, large accumulated losses, and substantial doubt about its ability to continue as a going concern absent new capital.
Propanc Biopharma, Inc. approved the issuance of specific restricted common shares to officers, directors and service providers and authorized a reverse stock split between 1-for-10 and 1-for-30.
The Board approved detailed New Stock Issuances on March 16, 2026, including 7,000,000 shares to James Nathanielsz and multiple grants of 2,000,000–2,500,000 shares to named recipients. The Board also approved a Reverse Stock Split in a ratio between 1:10 and 1:30. As of March 16, 2026, there were 20,900,649 shares of Common Stock outstanding; the Majority Stockholder (holding 8,732 common shares and 1 Series B Preferred share) voted in favor, representing approximately 50.01% of voting power.
Propanc Biopharma, Inc. notifies shareholders that its Board and the holder of a majority of voting power approved two corporate actions by written consent: (1) the issuance of restricted Common Stock to officers, directors and service providers and (2) a reverse stock split at a ratio between 1:10 and 1:30.
The Information Statement lists specific New Stock Issuances totaling 33,000,000 shares (7,000,000 to James Nathanielsz and multiple allocations of 2,000,000 and 2,500,000 shares to others) and states there were 20,900,649 shares outstanding as of March 16, 2026. The Majority Stockholder (holding 8,732 common shares and 1 share of Series B Preferred) voted in favor, representing approximately 50.01% of the voting equity.